Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

A gain-of-function mutation of JAK2 in myeloproliferative disorders.

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.

MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

Elucidating Compound Mechanism of Action by Network Perturbation Analysis

Pharmacologic Blockade of JAK1/JAK2 Reduces GvHD and Preserves the Graft-Versus-Leukemia Effect

Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings.

Octa-Arginine Mediated Delivery of Wild-Type Lnk Protein Inhibits TPO-Induced M-MOK Megakaryoblastic Leukemic Cell Growth by Promoting Apoptosis

JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor

Modulation of STAT3 and STAT5 activity rectifies the imbalance of Th17 and Treg cells in patients with acute coronary syndrome.

The transcriptional modulator BCL6 as a molecular target for breast cancer therapy

INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.

Jak2 Tyrosine Kinase: A Potential Therapeutic Target for AT1 Receptor Mediated Cardiovascular Disease

Real-time bioluminescence imaging of polycythemia vera development in mice.

A gain-of-function mutation of JAK2 in myeloproliferative disorders.

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.

MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

Elucidating Compound Mechanism of Action by Network Perturbation Analysis

Pharmacologic Blockade of JAK1/JAK2 Reduces GvHD and Preserves the Graft-Versus-Leukemia Effect

Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings.

Octa-Arginine Mediated Delivery of Wild-Type Lnk Protein Inhibits TPO-Induced M-MOK Megakaryoblastic Leukemic Cell Growth by Promoting Apoptosis

JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor

Modulation of STAT3 and STAT5 activity rectifies the imbalance of Th17 and Treg cells in patients with acute coronary syndrome.

The transcriptional modulator BCL6 as a molecular target for breast cancer therapy

INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.

Jak2 Tyrosine Kinase: A Potential Therapeutic Target for AT1 Receptor Mediated Cardiovascular Disease

Real-time bioluminescence imaging of polycythemia vera development in mice.

A gain-of-function mutation of JAK2 in myeloproliferative disorders.

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.

MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.